Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
KDMF
0
NDC API
0
VMF
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 1-methyl-7-nitro-5-phenyl-1,3-dihydro-2h-1,4- Benzodiazepin-2-one
2. Hypnon
3. S-1530
1. 2011-67-8
2. 1-methylnitrazepam
3. Elimin
4. Erimin
5. Methylnitrazepam
6. 1,3-dihydro-1-methyl-7-nitro-5-phenyl-2h-1,4-benzodiazepin-2-one
7. Nimetazepamum
8. Ro 5-3453
9. S 1530
10. 1-methyl-5-phenyl-7-nitro-1,3-dihydro-2h-1,4-benzodiazepin-2-one
11. 1-methyl-7-nitro-5-phenyl-1,3-dihydro-2h-1,4-benzodiazepin-2-one
12. 1-methyl-7-nitro-5-phenyl-3h-1,4-benzodiazepin-2-one
13. S-1530
14. 2h-1,4-benzodiazepin-2-one, 1,3-dihydro-1-methyl-7-nitro-5-phenyl-
15. Chebi:31912
16. Ncgc00164577-01
17. 4532264kw6
18. Dsstox_cid_3369
19. Dsstox_rid_76997
20. Dsstox_gsid_23369
21. Nimetazepam [inn:jan]
22. Nimetazepamum [inn-latin]
23. Smr000238177
24. Cas-2011-67-8
25. Einecs 217-931-5
26. Brn 0759813
27. Dormalon
28. Dea No. 2837
29. Unii-4532264kw6
30. Erimin (tn)
31. Nitrazepam, Methylated
32. Nimetazepam (jan/inn)
33. Nimetazepam [mi]
34. Nimetazepam [inn]
35. Nimetazepam [jan]
36. Nimetazepam [mart.]
37. Schembl79886
38. Nimetazepam [who-dd]
39. Mls000759521
40. Mls001424150
41. Chembl13341
42. Dtxsid6023369
43. Hms2051l16
44. Hms3393l16
45. Zinc3831205
46. Tox21_112205
47. Akos030239804
48. Tox21_112205_1
49. Ccg-101044
50. Nc00294
51. Ncgc00164577-02
52. D01593
53. 011n678
54. A814257
55. Q6149812
56. 1-methyl-7-nitro-5-phenyl-2,3-dihydro-1h-1,4-benzodiazepin-2-one
57. 7-nitro-1,3-dihydro-1-methyl-5-phenyl-2h-1,4-benzodiazepin-2-one
58. Nimetazepam Solution, 1.0 Mg/ml In Methanol, Ampule Of 1 Ml, Certified Reference Material
| Molecular Weight | 295.29 g/mol |
|---|---|
| Molecular Formula | C16H13N3O3 |
| XLogP3 | 2.2 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 1 |
| Exact Mass | 295.09569129 g/mol |
| Monoisotopic Mass | 295.09569129 g/mol |
| Topological Polar Surface Area | 78.5 Ų |
| Heavy Atom Count | 22 |
| Formal Charge | 0 |
| Complexity | 480 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Anticonvulsants
Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)
GABA Modulators
Substances that do not act as agonists or antagonists but do affect the GAMMA-AMINOBUTYRIC ACID receptor-ionophore complex. GABA-A receptors (RECEPTORS, GABA-A) appear to have at least three allosteric sites at which modulators act: a site at which BENZODIAZEPINES act by increasing the opening frequency of GAMMA-AMINOBUTYRIC ACID-activated chloride channels; a site at which BARBITURATES act to prolong the duration of channel opening; and a site at which some steroids may act. GENERAL ANESTHETICS probably act at least partly by potentiating GABAergic responses, but they are not included here. (See all compounds classified as GABA Modulators.)
Hypnotics and Sedatives
Drugs used to induce drowsiness or sleep or to reduce psychological excitement or anxiety. (See all compounds classified as Hypnotics and Sedatives.)
Anti-Anxiety Agents
Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. (See all compounds classified as Anti-Anxiety Agents.)
N - Nervous system
N05 - Psycholeptics
N05C - Hypnotics and sedatives
N05CD - Benzodiazepine derivatives
N05CD15 - Nimetazepam
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
ABOUT THIS PAGE
A Nimetazepam manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Nimetazepam, including repackagers and relabelers. The FDA regulates Nimetazepam manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Nimetazepam API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Nimetazepam manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Nimetazepam supplier is an individual or a company that provides Nimetazepam active pharmaceutical ingredient (API) or Nimetazepam finished formulations upon request. The Nimetazepam suppliers may include Nimetazepam API manufacturers, exporters, distributors and traders.
click here to find a list of Nimetazepam suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Nimetazepam written confirmation (Nimetazepam WC) is an official document issued by a regulatory agency to a Nimetazepam manufacturer, verifying that the manufacturing facility of a Nimetazepam active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Nimetazepam APIs or Nimetazepam finished pharmaceutical products to another nation, regulatory agencies frequently require a Nimetazepam WC (written confirmation) as part of the regulatory process.
click here to find a list of Nimetazepam suppliers with Written Confirmation (WC) on PharmaCompass.
Nimetazepam Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Nimetazepam GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Nimetazepam GMP manufacturer or Nimetazepam GMP API supplier for your needs.
A Nimetazepam CoA (Certificate of Analysis) is a formal document that attests to Nimetazepam's compliance with Nimetazepam specifications and serves as a tool for batch-level quality control.
Nimetazepam CoA mostly includes findings from lab analyses of a specific batch. For each Nimetazepam CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Nimetazepam may be tested according to a variety of international standards, such as European Pharmacopoeia (Nimetazepam EP), Nimetazepam JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Nimetazepam USP).
LOOKING FOR A SUPPLIER?
